Related Experiment Video
Updated: Jul 6, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
Published on: May 10, 2018
Varenicline may trigger severe hypoglycaemia in Type 1 diabetes
P L Kristensen1, U Pedersen-Bjergaard, B Thorsteinsson
1Endocrinology Section, Division of Internal Medicine, Hillerød Hospital, Hillerød, Denmark. pelk@noh.regionh.dk
Background:
Varenicline is a new drug indicated for smoking cessation. It has primarily been investigated in healthy adults. The commonest side-effects are nausea, headache, sleep disturbance, constipation, flatulence and vomiting. Hypoglycaemia has not been reported. As smoking cessation is important to reduce risk of cardiovascular morbidity, especially in diabetes, use of effective drugs indicated for smoking cessation is rational.
Case Report:
We report multiple episodes of severe hypoglycaemia after starting varenicline in a 53-year-old woman with Type 1 diabetes. Since onset of diabetes at age 25 years and until start of varenicline therapy, she had only experienced one episode of severe hypoglycaemia and hypoglycaemia awareness was not impaired. The severe hypoglycaemic episodes disappeared after withdrawal of varenicline.
Conclusions:
We recommend cautious prescription of varenicline, intensified blood glucose monitoring and careful education of patients with diabetes treated with varenicline. Further investigation of the use of varenicline in patients with diabetes is warranted.
Related Concept Videos
Hypoglycemia
Oral Hypoglycemic Agents: Biguanides and Glitazones
Hypoglycemia and Glucagon
Type I Diabetes III: Clinical Manifestations
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Oral Hypoglycemic Agents: Glinides